Cargando…
Advances in RIPK1 kinase inhibitors
Programmed necrosis is a new modulated cell death mode with necrotizing morphological characteristics. Receptor interacting protein 1 (RIPK1) is a critical mediator of the programmed necrosis pathway that is involved in stroke, myocardial infarction, fatal systemic inflammatory response syndrome, Al...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554302/ https://www.ncbi.nlm.nih.gov/pubmed/36249746 http://dx.doi.org/10.3389/fphar.2022.976435 |
_version_ | 1784806663111311360 |
---|---|
author | Chen, Lu Zhang, Xiaoqin Ou, Yaqing Liu, Maoyu Yu, Dongke Song, Zhiheng Niu, Lihong Zhang, Lijuan Shi, Jianyou |
author_facet | Chen, Lu Zhang, Xiaoqin Ou, Yaqing Liu, Maoyu Yu, Dongke Song, Zhiheng Niu, Lihong Zhang, Lijuan Shi, Jianyou |
author_sort | Chen, Lu |
collection | PubMed |
description | Programmed necrosis is a new modulated cell death mode with necrotizing morphological characteristics. Receptor interacting protein 1 (RIPK1) is a critical mediator of the programmed necrosis pathway that is involved in stroke, myocardial infarction, fatal systemic inflammatory response syndrome, Alzheimer’s disease, and malignancy. At present, the reported inhibitors are divided into four categories. The first category is the type I ATP-competitive kinase inhibitors that targets the area occupied by the ATP adenylate ring; The second category is type Ⅱ ATP competitive kinase inhibitors targeting the DLG-out conformation of RIPK1; The third category is type Ⅲ kinase inhibitors that compete for binding to allosteric sites near ATP pockets; The last category is others. This paper reviews the structure, biological function, and recent research progress of receptor interaction protein-1 kinase inhibitors. |
format | Online Article Text |
id | pubmed-9554302 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95543022022-10-13 Advances in RIPK1 kinase inhibitors Chen, Lu Zhang, Xiaoqin Ou, Yaqing Liu, Maoyu Yu, Dongke Song, Zhiheng Niu, Lihong Zhang, Lijuan Shi, Jianyou Front Pharmacol Pharmacology Programmed necrosis is a new modulated cell death mode with necrotizing morphological characteristics. Receptor interacting protein 1 (RIPK1) is a critical mediator of the programmed necrosis pathway that is involved in stroke, myocardial infarction, fatal systemic inflammatory response syndrome, Alzheimer’s disease, and malignancy. At present, the reported inhibitors are divided into four categories. The first category is the type I ATP-competitive kinase inhibitors that targets the area occupied by the ATP adenylate ring; The second category is type Ⅱ ATP competitive kinase inhibitors targeting the DLG-out conformation of RIPK1; The third category is type Ⅲ kinase inhibitors that compete for binding to allosteric sites near ATP pockets; The last category is others. This paper reviews the structure, biological function, and recent research progress of receptor interaction protein-1 kinase inhibitors. Frontiers Media S.A. 2022-09-28 /pmc/articles/PMC9554302/ /pubmed/36249746 http://dx.doi.org/10.3389/fphar.2022.976435 Text en Copyright © 2022 Chen, Zhang, Ou, Liu, Yu, Song, Niu, Zhang and Shi. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Chen, Lu Zhang, Xiaoqin Ou, Yaqing Liu, Maoyu Yu, Dongke Song, Zhiheng Niu, Lihong Zhang, Lijuan Shi, Jianyou Advances in RIPK1 kinase inhibitors |
title | Advances in RIPK1 kinase inhibitors |
title_full | Advances in RIPK1 kinase inhibitors |
title_fullStr | Advances in RIPK1 kinase inhibitors |
title_full_unstemmed | Advances in RIPK1 kinase inhibitors |
title_short | Advances in RIPK1 kinase inhibitors |
title_sort | advances in ripk1 kinase inhibitors |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554302/ https://www.ncbi.nlm.nih.gov/pubmed/36249746 http://dx.doi.org/10.3389/fphar.2022.976435 |
work_keys_str_mv | AT chenlu advancesinripk1kinaseinhibitors AT zhangxiaoqin advancesinripk1kinaseinhibitors AT ouyaqing advancesinripk1kinaseinhibitors AT liumaoyu advancesinripk1kinaseinhibitors AT yudongke advancesinripk1kinaseinhibitors AT songzhiheng advancesinripk1kinaseinhibitors AT niulihong advancesinripk1kinaseinhibitors AT zhanglijuan advancesinripk1kinaseinhibitors AT shijianyou advancesinripk1kinaseinhibitors |